Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Yale B Mitchel"'
Publikováno v:
Journal of Lipid Research, Vol 49, Iss 12, Pp 2641-2647 (2008)
This analysis evaluates the effects on lipoprotein subfractions and LDL particle size of ezetimibe/simvastatin with or without coadministration of fenofibrate in patients with mixed hyperlipidemia. This multicenter, double-blind, placebo-controlled,
Externí odkaz:
https://doaj.org/article/a0ba5d874ffe475e9f58f04538221fc8
Autor:
Siddharth M Patel, Christopher P Cannon, KyungAh Im, Michael A Blazing, Yale B Mitchel, Marc S Sabatine, Robert P Giugliano, Erin A Bohula
Publikováno v:
Circulation. 144
Introduction: Ezetimibe (EZE) added to statin further reduces LDL-C and CV events. Prior studies demonstrated large inter-individual variability in LDL-C reduction with statins. Whether similar variability exists with EZE has not been reported in a l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1853563bd5c6d7b0088251db1ce35e3
https://doi.org/10.1161/circ.144.suppl_1.11524
https://doi.org/10.1161/circ.144.suppl_1.11524
Autor:
Yale B. Mitchel, Jennifer A. White, Robert P. Giugliano, Ping He, Eugene Braunwald, Jeong-Gun Park, Michael A. Blazing, Sabina A. Murphy, David A. Morrow, Terje R. Pedersen, Adrian J B Brady, Christopher P. Cannon, Y. Antero Kesäniemi, Erin A. Bohula
Publikováno v:
Journal of the American College of Cardiology. 69:911-921
Background Ezetimibe improves cardiovascular (CV) outcomes in patients stabilized after acute coronary syndrome (ACS) when added to statin therapy. After ACS, patients vary considerably in their risk for recurrent CV events. Objectives This study tes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f46f8d0fd97ae1032f9eaae4db95a16
https://doi.org/10.1016/j.jacc.2016.11.070
https://doi.org/10.1016/j.jacc.2016.11.070
Autor:
Christopher P. Cannon, Michael A. Blazing, Yuliya Lokhnygina, Ann Marie Navar, Thomas Musliner, Michael G. Nanna, Jennifer A. White, Robert P. Giugliano, Yale B. Mitchel
Publikováno v:
J Am Coll Cardiol
Muscle-related events, including less severe muscle complaints without a clear pharmacological relationship to the treatment, may hamper compliance with lipid-lowering therapy and increase the risk of drug discontinuation ([1][1]). In IMPROVE-IT (Imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::882878a9fc9e578f814da26ca7eb4252
https://pubmed.ncbi.nlm.nih.gov/32081289
https://pubmed.ncbi.nlm.nih.gov/32081289
Autor:
J. Fable, Joost Besseling, Yale B. Mitchel, John J.P. Kastelein, A. Sapre, A.O. Johnson-Levonas, S. Shah
Publikováno v:
European Heart Journal. 38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d294bc0d2ac7dc7b15adaace93b771b1
https://doi.org/10.1093/eurheartj/ehx501.p637
https://doi.org/10.1093/eurheartj/ehx501.p637
Autor:
Eliot A. Brinton, Antonio M. Gotto, Jennifer Moon, Philip J. Barter, Uma Kher, Sukrut Shah, Manash Shankar Chatterjee, Yang Liu, Christopher P. Cannon, Yale B. Mitchel, Xiujiang Susie Li, Sanskruti Vaidya, Hayes M. Dansky
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 19:543-549
Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that has previously been shown to reduce low-density lipoprotein cholesterol (LDL-C) and raise high-density lipoprotein cholesterol (HDL-C) in patients with or at high risk of coron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6136bb88d55b26e0d226f8db9e62d6a
https://doi.org/10.1177/1074248414529621
https://doi.org/10.1177/1074248414529621
Autor:
Sukrut Shah, Ignacio Rodriguez Briones, Tanya B. Ashraf, Yale B. Mitchel, Yugang Dong, Wayne Huey-Heng Sheu, Sandra C. Tobias, Tayfun Sahin, Amy O. Johnson-Levonas, Yulia Moiseeva, P Rossi, Duk-Hyun Kang, Aditi Sapre, Christie M. Ballantyne, Ping Ye
Publikováno v:
The American journal of cardiology. 120(4)
This phase 3, multiregional, randomized, double-blind, placebo-controlled study assessed the efficacy/safety profile of anacetrapib added to ongoing therapy with statin ± other lipid-modifying therapies in patients with hypercholesterolemia who were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f88f7c89349f6b460508da7c4b7b87a
https://pubmed.ncbi.nlm.nih.gov/28624096
https://pubmed.ncbi.nlm.nih.gov/28624096
Autor:
Alexandra MacLean, Philippe Brudi, Darbie Maccubbin, Joseph Triscari, Erluo Chen, Eliot A. Brinton, Yale B. Mitchel, Amy O. Johnson-Levonas, Christine McCrary Sisk, Rae Ann Ruck
Publikováno v:
Lipids in Health and Disease
Background LDL-C, non-HDL-C and ApoB levels are inter-correlated and all predict risk of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM) and/or high TG. These levels are lowered by extended-release niac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5708d6295d072da097af4747b67f5fcd
http://europepmc.org/articles/PMC4942972
http://europepmc.org/articles/PMC4942972
Autor:
Anders G. Olsson, Fabian Chen, Christine McCrary Sisk, Waheeda Sirah, Darbie Maccubbin, Yale B. Mitchel, Harold E. Bays, Jennifer W. Anderson, Uma Kher
Publikováno v:
The American Journal of Cardiology. 110:817-822
Extended-release niacin (ERN) improves multiple lipid parameters but is underused owing to niacin-induced flushing (NIF). Laropiprant (LRPT) reduces NIF; however, its effects on chronic flushing (6 months) have not been studied. We examined whether a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10a674cd0221eb79ff78d7163537321c
https://doi.org/10.1016/j.amjcard.2012.05.009
https://doi.org/10.1016/j.amjcard.2012.05.009
Autor:
Nancy Liu, Amy O. Johnson-Levonas, Christine McCrary Sisk, Gilbert W. Gleim, Yale B. Mitchel, Christie M. Ballantyne
Publikováno v:
Journal of Clinical Lipidology. 6:235-243
Background The use of extended-release niacin and the prostaglandin D 2 receptor antagonist laropiprant (ERN/LRPT) reduces niacin-induced flushing in patients while preserving its lipid-modifying effects. Objective This predefined exploratory analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9f1c7aebba71625b7beca1bb682d636
https://doi.org/10.1016/j.jacl.2011.11.004
https://doi.org/10.1016/j.jacl.2011.11.004